Public appeal to energy companies to provide aid to 28-02-2023, 15:51

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Liquidia Corporation to Report Full Year 2022 Financial 9-03-2023, 19:27